KR102663613B1 - Composition for preventing or treating of feline infectious peritonitis comprising Schizonepeta tenuifolia extract as an active ingredient - Google Patents
Composition for preventing or treating of feline infectious peritonitis comprising Schizonepeta tenuifolia extract as an active ingredient Download PDFInfo
- Publication number
- KR102663613B1 KR102663613B1 KR1020220131822A KR20220131822A KR102663613B1 KR 102663613 B1 KR102663613 B1 KR 102663613B1 KR 1020220131822 A KR1020220131822 A KR 1020220131822A KR 20220131822 A KR20220131822 A KR 20220131822A KR 102663613 B1 KR102663613 B1 KR 102663613B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- feline
- infectious peritonitis
- active ingredient
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 208000005098 feline infectious peritonitis Diseases 0.000 title claims abstract description 42
- 239000004480 active ingredient Substances 0.000 title claims abstract description 25
- 239000000284 extract Substances 0.000 title abstract description 40
- 241000951376 Schizonepeta tenuifolia Species 0.000 title description 3
- 241000725579 Feline coronavirus Species 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 241000282326 Felis catus Species 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 235000013402 health food Nutrition 0.000 claims abstract description 8
- 241000124008 Mammalia Species 0.000 claims description 19
- 235000019730 animal feed additive Nutrition 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 230000000840 anti-viral effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 239000000469 ethanolic extract Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 239000000645 desinfectant Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- -1 wet tissues Substances 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000030833 cell death Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 108700010904 coronavirus proteins Proteins 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000003674 animal food additive Substances 0.000 abstract description 3
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000126 substance Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241000282324 Felis Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940052200 mold extract Drugs 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000711573 Coronaviridae Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002137 ultrasound extraction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000207923 Lamiaceae Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 208000010717 cat disease Diseases 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- CQAIPTBBCVQRMD-UHFFFAOYSA-L dipotassium;phosphono phosphate Chemical compound [K+].[K+].OP(O)(=O)OP([O-])([O-])=O CQAIPTBBCVQRMD-UHFFFAOYSA-L 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000007446 host cell death Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Polymers [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Abstract
본 발명은 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 예방 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 고양이 코로나바이러스의 성장 억제 및 고양이 코로나바이러스에 의한 세포 사멸 억제 능력이 우수한 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 예방 또는 치료용 수의학적 조성물, 사료 첨가제, 건강식품 조성물 및 이를 투여하여 고양이 전염성 복막염을 치료하는 방법에 관한 것이다.
형개 추출물을 유효성분으로 포함하는 본 발명의 조성물은 고양이 코로나바이러스 단백질의 발현을 억제하고, 고양이 코로나바이러스에 의한 세포 사멸을 억제하는 활성이 우수하므로, 고양이 전염성 복막염의 예방 또는 치료제 개발에 유용하게 활용될 수 있다. The present invention relates to a composition for the prevention or treatment of feline infectious peritonitis, comprising a feline infectious peritonitis extract as an active ingredient. More specifically, the present invention relates to a composition for the prevention or treatment of feline infectious peritonitis, which contains an extract of the feline coronavirus, which is excellent in the ability to inhibit the growth of feline coronavirus and inhibit cell death caused by feline coronavirus, as an active ingredient. It relates to a veterinary composition, feed additive, health food composition for preventing or treating feline infectious peritonitis, and a method of treating feline infectious peritonitis by administering the same.
The composition of the present invention containing the extract of the cat as an active ingredient has excellent activity in suppressing the expression of feline coronavirus protein and inhibiting cell death caused by feline coronavirus, so it is useful in the prevention or development of treatment for feline infectious peritonitis. It can be.
Description
본 발명은 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 예방 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 고양이 코로나바이러스의 성장 억제 및 고양이 코로나바이러스에 의한 세포 사멸 억제 능력이 우수한 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 예방 또는 치료용 수의학적 조성물, 사료 첨가제, 건강식품 조성물 및 이를 투여하여 고양이 전염성 복막염을 치료하는 방법에 관한 것이다. The present invention relates to a composition for the prevention or treatment of feline infectious peritonitis, comprising a feline infectious peritonitis extract as an active ingredient. More specifically, the present invention relates to a composition for the prevention or treatment of feline infectious peritonitis, which contains an extract of the feline coronavirus, which is excellent in the ability to inhibit the growth of feline coronavirus and inhibit cell death caused by feline coronavirus, as an active ingredient. It relates to a veterinary composition, feed additive, health food composition for preventing or treating feline infectious peritonitis, and a method of treating feline infectious peritonitis by administering the same.
고양이 전염성 복막염은 생후 1살 이전의 어린 고양이과 동물에서 주로 발병하며, 유발율이 17% 정도이지만 치사율은 거의 100%에 달하여 고양이 질병 중 가장 치명적이고 치료가 어려운 질병이다. 발병 시 식욕 부진, 발열, 황달, 설사, 체중감소, 신경 증상 및 포도막염과 같은 임상증상을 나타내고 점차 복수가 차며 호흡곤란이 일어나지만, 병의 진행이 느려 증상이 매우 천천히 나타나므로 조기에 발견하기가 힘들다. 또한 일단 발병하면 적절한 치료 방법이 알려져 있지 않고 사망률이 매우 높은 매우 치명적인 질병이다. Feline infectious peritonitis mainly occurs in young felines before the age of one year, and the incidence rate is about 17%, but the mortality rate is almost 100%, making it the most fatal and difficult to treat among cat diseases. At the onset, clinical symptoms such as loss of appetite, fever, jaundice, diarrhea, weight loss, neurological symptoms, and uveitis appear, and gradually ascites builds up and difficulty breathing occurs. However, the disease progresses slowly and symptoms appear very slowly, making early detection difficult. it's tough. Additionally, once it develops, it is a very fatal disease with no known appropriate treatment method and a very high mortality rate.
고양이 전염성 복막염(FIP)은 코로나바이러스의 일종인 고양이 전염성 복막염 바이러스(Feline Infectious Peritonitis Virus, FIPV)에 의해 발병하는데, FIPV는 세포와 조직에 강하게 결합하여 신장의 집합관이나 장벽에 병변 발생을 일으키고 오염된 음식이나, 침구, 소변이나 대변을 통해 전염되는 것을 특징으로 한다. 감염된 개체는 초기에 상당 기간 무증상으로 질병 매개자의 역할을 하여 장기간 바이러스를 확산시킬 수 있는 전파의 위험성이 높다.Feline Infectious Peritonitis (FIP) is caused by Feline Infectious Peritonitis Virus (FIPV), a type of coronavirus. FIPV binds strongly to cells and tissues, causing lesions in the collecting ducts and intestinal walls of the kidneys, and causing contamination. It is characterized by being transmitted through food, bedding, urine or feces. Infected individuals are initially asymptomatic for a considerable period of time and act as disease carriers, raising the risk of transmission that can spread the virus for a long period of time.
FIPV는 또 다른 고양이 코로나바이러스(FCoV)로서 장세포에서만 감염 및 복제하여 숙주 고양이의 설사를 유발하는 고양이 장 코로나바이러스(Feline Enteric Coronavirus, FECV)가 고양이에게 감염된 뒤, 자발적으로 돌연변이를 일으켜 대식세포로의 감염이 가능하도록 변형된 바이러스로 알려져 있다(Licitra, Beth N et al. "Mutation in spike protein cleavage site and pathogenesis of feline coronavirus." Emerging infectious diseases vol.19,7 (2013): 1066-73). 따라서 FIPV는 FECV와 거의 유사한 바이러스이며, 원인이 되는 FECV를 제거함으로써 FIPV의 형성 및 고양이 전염성 복막염을 막을 수 있다.FIPV is another feline coronavirus (FCoV). Feline enteric coronavirus (FECV) infects and replicates only in enterocytes and causes diarrhea in host cats. After infection in cats, it spontaneously mutates and becomes a macrophage. It is known to be a virus that has been modified to enable infection (Licitra, Beth N et al. "Mutation in spike protein cleavage site and pathogenesis of feline coronavirus." Emerging infectious diseases vol.19,7 (2013): 1066-73). Therefore, FIPV is a virus that is almost similar to FECV, and the formation of FIPV and feline infectious peritonitis can be prevented by eliminating the causative FECV.
현재, FIP의 치료를 위해 승인된 백신 또는 효과적인 항바이러스 요법은 존재하지 않는다. 따라서, 고양이에서 FIP를 치료하거나, 그 발병 원인이 되는 FIPV 혹은 FECV를 치료하는 화합물의 개발에 대한 상당한 필요가 존재한다.Currently, there are no approved vaccines or effective antiviral therapies for the treatment of FIP. Therefore, there is a significant need for the development of compounds to treat FIP in cats, or to treat the FIPV or FECV that causes it.
한편, 형개(Schizonepeta tenuifolia)는 꿀풀과의 1년초로, 주성분은 정유성분으로 d-멘톤(d-menthone), d1-멘톤(dl-menthone)과 소량의 d-리모넨(dlimonene)이 있으며, 그 밖에 헤페리딘(heperidine), 우르솔산(ursolic acid), 루테올린(luteolin), 다우세스테롤(daucesterol) 등이 보고되었다(Zhang YH, et al., Zhongguo Zhong Yao Za Zhi., 31(15), pp1247-57, 2006). 형개 추출물은 항히스타민 작용과 항소양증 작용을 나타낸다고 보고 되었고(Tohda C, et al., Biol Pharm Bull., 23(5), pp599-601, 2000), 주성분인 필수지방은 항충작용 및 항진균 작용을 나타낸다는 것이 보고된바 있다(Park IK. et al., J Econ Entomol., 99(5), pp1717-21, 2006).Meanwhile, Schizonepeta tenuifolia is an annual herb of the Lamiaceae family. Its main components are essential oils, including d-menthone, dl-menthone, and a small amount of d-limonene. In addition, heperidine, ursolic acid, luteolin, and daucesterol have been reported (Zhang YH, et al., Zhongguo Zhong Yao Za Zhi., 31(15) , pp1247-57, 2006). Hyeonggae extract has been reported to have antihistamine and antipruritic effects (Tohda C, et al., Biol Pharm Bull., 23(5), pp599-601, 2000), and essential fat, the main ingredient, has antifungal and antifungal effects. It has been reported (Park IK. et al., J Econ Entomol., 99(5), pp1717-21, 2006).
이에 본 발명자들은 고양이 전염성 복막염을 치료할 수 있는 물질을 탐색하고자 노력한 결과, 형개 추출물이 FIPV와 유사한 것으로서 FIPV의 유래가 되는 FECV 단백질의 발현을 억제하고, FECV에 의한 숙주세포 사멸을 감소시킴을 확인하여 본 발명을 완성하였다.Accordingly, the present inventors tried to search for a substance that can treat feline infectious peritonitis, and as a result, it was confirmed that the extract of the snail is similar to FIPV, inhibits the expression of the FECV protein from which FIPV is derived, and reduces host cell death caused by FECV. The present invention has been completed.
따라서, 본 발명의 목적은 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염(feline infectious peritonitis, FIP) 예방 또는 치료용 수의학적 조성물, 동물사료 첨가제 또는 건강식품 조성물을 제공하는 것이다. Accordingly, the purpose of the present invention is to provide a veterinary composition, animal feed additive, or health food composition for preventing or treating feline infectious peritonitis (FIP), which contains a cat extract as an active ingredient.
본 발명의 다른 목적은 인간을 제외한 포유동물에 형개 추출물을 유효성분으로 포함하는 조성물을 투여하는 단계를 포함하는, 고양이 전염성 복막염 치료방법을 제공하는 것이다. Another object of the present invention is to provide a method for treating feline infectious peritonitis, comprising administering a composition containing a cypress extract as an active ingredient to a mammal other than a human.
본 발명의 다른 목적은 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 바이러스에 대한 항바이러스용 조성물을 제공하는 것이다. Another object of the present invention is to provide an antiviral composition against feline infectious peritonitis virus containing a cat extract as an active ingredient.
상기와 같은 목적을 달성하기 위하여, 본 발명은 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염(feline infectious peritonitis, FIP) 예방 또는 치료용 수의학적 조성물, 동물사료 첨가제 또는 건강식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a veterinary composition, animal feed additive, or health food composition for preventing or treating feline infectious peritonitis (FIP), which contains a cat extract as an active ingredient.
본 발명의 다른 목적을 달성하기 위하여, 본 발명은 인간을 제외한 포유동물에 형개 추출물을 유효성분으로 포함하는 조성물을 투여하는 단계를 포함하는, 고양이 전염성 복박염 치료 방법을 제공한다.In order to achieve another object of the present invention, the present invention provides a method of treating infectious feline peritonitis, comprising administering a composition containing a snail extract as an active ingredient to a mammal other than a human.
본 발명의 또 다른 목적을 달성하기 위하여, 본 발명은 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복박염 바이러스에 대한 항바이러스용 조성물을 제공한다.In order to achieve another object of the present invention, the present invention provides an antiviral composition against feline infectious mucositis virus containing a cat extract as an active ingredient.
이하 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 일 실시예에 따르면, 형개 추출물은 코로나바이러스 단백질의 발현을 억제하여 고양이 장 코로나바이러스(FEPV)의 증식을 억제하고, FECV 감염 세포의 세포사멸을 억제하는 효과를 가지고 있음이 확인되었다.According to one embodiment of the present invention, it was confirmed that the extract of Hyeonggeo suppresses the expression of coronavirus proteins, inhibits the proliferation of feline enteric coronavirus (FEPV), and inhibits apoptosis of FECV-infected cells.
따라서, 본 발명은 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 예방 또는 치료용 수의학적 조성물을 제공한다.Accordingly, the present invention provides a veterinary composition for preventing or treating feline infectious peritonitis, comprising an extract of the cat as an active ingredient.
본 발명에서 상기 "형개"(Schizonepeta tenuifolia)는 꿀풀과(Labiatae)의 꽃이삭으로서, 가늘고 긴 보리이삭 모양을 가지고 있으며, 길이는 5~10cm 정도이고, 보라색을 띈 녹갈색의 식물이다. 작은 입술꽃과 때로 열매를 갖는 꽃받침 통이 붙어 있으며, 식물 전체에 유백색의 짧은 털을 가지고 있다. 본 식물은 특유한 냄새가 있고 입 속에 넣으면 약간 시원한 느낌이 나는 특징을 가지고 있다. 형개 추출물은 항히스타민 작용과 항소양증 작용을 나타내는 것으로 보고되고 있고, 주성분인 필수지방은 항충작용 및 항진균 작용을 나타낸다는 것이 보고된 바 있다.In the present invention, the "hyeonggae" ( Schizonepeta tenuifolia ) is a flower ear of the Lamiaceae family ( Labiatae ), has the shape of a thin and long barley ear, is about 5 to 10 cm long, and is a purple-greenish-brown plant. It has small lipped flowers and sometimes fruit-bearing calyx tubes, and the entire plant has milky white short hairs. This plant has a unique smell and has the characteristic of giving a slightly cool feeling when put in the mouth. Hyeonggae extract has been reported to exhibit antihistamine and antipruritic effects, and its main ingredient, essential fat, has been reported to exhibit antiparasitic and antifungal effects.
본 발명에서 상기 "형개 추출물"은 초음파 추출법을 이용하여 추출하는 것이 바람직하고, 특히 상기 초음파 추출법에 있어서 용매는 탄소수 1 내지 6개의 알코올(alcohol), 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane), 시클로헥산(cyclohexane) 및 석유에테르(petroleum ether)로 이루어진 군에서 선택된 어느 하나를 이용하는 것이 바람직하며, 가장 바람직하게는 에탄올을 이용하여 초음파 추출법에 의해 추출한 것이다.In the present invention, the "mold extract" is preferably extracted using an ultrasonic extraction method. In particular, in the ultrasonic extraction method, the solvent is alcohol having 1 to 6 carbon atoms, acetone, ether, and benzene ( It is preferable to use any one selected from the group consisting of benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, and petroleum ether. And most preferably, it is extracted by ultrasonic extraction using ethanol.
본 발명의 추출물은 여과 및/또는 농축하여 액상으로 사용하거나, 분무건조 또는 동결건조 등 통상의 건조 공정을 통해 고형화하여 사용할 수 있다. 상기 건조 공정에서는 분무건조 또는 동결건조 전 덱스트린 등을 혼합하여 건조할 수 있다.The extract of the present invention can be used in liquid form by filtering and/or concentrating, or can be solidified through a conventional drying process such as spray drying or freeze drying. In the drying process, dextrin, etc. may be mixed and dried before spray drying or freeze drying.
본 발명에서 사용되는 용어, "치료" 또는 "치료하는 것" 이란, 포유동물에게 치료제 즉, 본 형개 추출물(단독으로 또는 다른 수의학적 제제와 결합하여)의 적용 또는 투여 또는 고양이 전염성 복막염, 고양이 전염성 복막염의 증상 또는 고양이 전염성 복막염으로 발전할 가능성이 있는 포유동물(예를 들면, 진단 또는 탈체 적용)로부터 치료, 치유, 완화, 경감, 변경, 해결, 개선, 향상 또는 고양이 전염성 복막염, 고양이 전염성 복막염의 증상 또는 고양이 전염성 복막염으로 발전될 가능성에 영향을 미치기 위한 목적을 가지고 포유동물, 분리된 조직 또는 세포주에 치료제의 적용 또는 투여로서 정의된다. 이러한 치료는 특히 게놈 약학의 분야로부터 얻어진 지식에 기초하여 맞춰지고 변경될 수 있다.As used in the present invention, the term "treatment" or "treating" refers to the application or administration of a therapeutic agent, i.e., this extract (alone or in combination with other veterinary preparations) to a mammal, or the treatment of feline infectious peritonitis, feline infectious disease, etc. Treatment, cure, alleviation, alleviation, alteration, resolution, amelioration, enhancement or treatment of feline infectious peritonitis, feline infectious peritonitis, or treatment of symptoms of peritonitis or in mammals likely to develop feline infectious peritonitis (e.g., diagnostic or disembodied applications). It is defined as the application or administration of a therapeutic agent to a mammal, isolated tissue or cell line with the purpose of affecting the symptoms or likelihood of developing feline infectious peritonitis. Such treatments can be tailored and modified based on knowledge gained, especially from the field of genomic medicine.
본 발명에서 사용되는 용어, "예방하다" 또는 "예방"이란, 만약 아무것도 일어나지 않았다면 장애 또는 질병 진전이 없는 것, 또는 이미 장애 또는 질병 진전이 있었다면 더 이상의 장애 또는 질병의 진전이 없는 것을 의미한다. 또한, 고려되는 것은 장애 또는 질병에 관련된 증상의 일부 또는 전부를 예방하는 하나의 능력이다.As used in the present invention, the term "prevent" or "prevention" means no disorder or disease progression if nothing has occurred, or no further disorder or disease progression if there has already been a disorder or disease progression. Also considered is one's ability to prevent some or all of the symptoms associated with a disorder or disease.
본 발명에서 사용되는 용어, "포유동물", "개체" 또는 "대상" 이란, 인간을 제외한 포유동물을 나타낸다. 예를 들면, 인간을 제외한 포유동물은 양 과, 소 과, 돼지 과, 개 과, 고양이 과 및 쥐 과의 포유동물와 같은 가축 및 애완동물을 포함한다. 바람직하게는 포유동물, 대상 또는 개체는 고양이일 수 있다. As used in the present invention, the terms “mammal,” “individual,” or “subject” refer to mammals other than humans. For example, mammals other than humans include domestic animals and pets, such as mammals of the sheep, bovine, swine, canine, feline, and rat families. Preferably the mammal, subject or individual may be a cat.
본 발명에서 사용되는 용어, "유효량", "수의학적 유효량" 및 "치료학적 유효량"이란, 원하는 생물학적 결과를 제공하는 제제의 무독성의 충분한 양을 나타낸다. 상기 결과는 신호, 증상 또는 질병의 원인의 감소 및/또는 약화이거나, 생물학적 시스템의 임의의 다른 원하는 변화일 수 있다. 임의의 개체의 경우에 적절한 치료 양은 통상의 실험을 사용하여 해당 기술분야에서 통상의 기술자에 의하여 결정될 수 있다.As used herein, the terms “effective amount,” “veterinary effective amount,” and “therapeutically effective amount” refer to a non-toxic sufficient amount of an agent to provide a desired biological result. The result may be a reduction and/or attenuation of the signs, symptoms or cause of the disease, or any other desired change in the biological system. The appropriate treatment amount for any subject can be determined by one of ordinary skill in the art using routine experimentation.
본 발명에서 사용되는 용어, "조성물" 또는 "수의학적 조성물"은 본 발명 내에서 형개 추출물 그 자체 또는 형개 추출물과 수의학적으로 허용 가능한 담체의 혼합물을 나타낸다. 수의학적 조성물은 포유동물 또는 대상에게 형개 추출물의 투여를 용이하게 한다. 이에 제한되지 않지만 정맥주사, 경구, 에어로졸, 비경구, 안구, 폐 및 국소의 투여를 포함하는 화합물을 투여하는 다양한 기술들이 해당 기술분야에 존재한다.As used herein, the term "composition" or "veterinary composition" refers within the present invention to the mold extract itself or a mixture of the mold extract and a veterinary acceptable carrier. The veterinary composition facilitates administration of the canine extract to a mammal or subject. A variety of techniques exist in the art for administering compounds, including but not limited to intravenous, oral, aerosol, parenteral, ocular, pulmonary, and topical administration.
본 발명에서 사용되는 용어, "수의학적으로 허용 가능한"이란, 화합물의 생물학적 활성 또는 특성을 저해하지 않고, 상대적으로 무독성인, 즉, 물질이 원하지 않는 생물학적 효과 또는 그것이 함유하고 있는 조성물의 임의의 구성성분과 해로운 방법으로 상호작용 없이 개체에게 투여될 수 있는 담체 또는 희석액과 같은 물질을 나타낸다.As used herein, the term "veterinary acceptable" refers to any component of a compound that does not inhibit the biological activity or properties of the compound and is relatively non-toxic, i.e., the undesirable biological effect of the substance or the composition it contains. It refers to a substance, such as a carrier or diluent, that can be administered to a subject without interacting in a detrimental way with the ingredient.
본 발명에서 사용되는 용어, "수의학적으로 허용 가능한 담체"는 본 발명 내에서 형개 추출물을 포유동물 내에서 또는 포유동물에게 그의 의도된 기능을 수행할 수 있도록 운반 또는 수송과 관련된 액체 또는 고체 필러, 안정제, 분산제, 현탁제, 희석액, 첨가제, 농조화제, 용매 또는 캡슐화 물질과 같은 수의학적으로 허용가능한 물질, 조성물 또는 담체를 의미한다. 전형적으로, 이러한 구성물은 하나의 기관 또는 신체의 일부로부터 신체의 다른 기관 또는 부분으로 운반되거나 수송된다. 각각의 담체는 본 발명 내에서 유용한 화합물을 포함하는 화학식의 다른 성분과 병용가능한 것 및 포유동물에게 손상을 주지 않는 관점에서 "허용 가능" 해야 한다. 수의학적으로 허용 가능한 담체로서 작용할 수 있는 물질의 일부 예는 다음을 포함한다: 수의학적 제형에 이용되는 락토오스, 글루코스 및 수크로오스와 같은 당류; 옥수수 전분 및 감자 전분과 같은 전분류; 셀룰로오스 및 소듐 카복시메틸 셀룰로오스, 에틸셀룰로오스 및 셀룰로오스 아세테이트와 같은 그의 유도체; 트래거캔스(tragacanth) 분말; 맥아; 젤라틴; 탈크; 코코아 버터 및 좌약 왁스와 같은 첨가제; 땅콩오일, 면실유, 홍화유, 참기름, 올리브 오일, 옥수수 오일 및 콩기름과 같은 오일; 플로필렌글리콜과 같은 글리콜; 글리세린, 솔비톨, 만니톨 및 폴리에틸렌글리콜과 같은 폴리올; 에틸올리에이트 및 에틸라우레이트와 같은 에스테르류; 한천; 마그네슘 하이드록사이드 및 알루미늄 하이드록사이드와 같은 완충제; 계면 활성제; 알긴산; 발열성 물질 제거수; 등장액; 링거 용액(Ringer's solution); 에틸알코올; 인산염 버퍼 용액; 및 다른 무독성의 병용가능한 물질. 또한, 본 발명에서 사용되는, "수의학적으로 허용 가능한 담체"는 본 발명내에서 유용한 화합물의 활성과 병용가능하고, 포유동물에게 생리학상으로 허용 가능한 일부 또는 전부 코팅제, 항바이러스제 및 항균제 및 흡수 지연제 등을 포함한다. 또한, 보충의 활성 화합물은 상기 조성물 내에 혼입될 수 있다. 본 발명의 실시에서 사용된 수의학적 조성물에 포함될 수 있는 다른 추가적인 성분은 해당 기술분야에 알려져 있고, 예를 들면, 참고문헌으로서 여기에 포함되어 있는 Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA)에 기술되어 있다.As used herein, the term "veterinary acceptable carrier" means, within the present invention, a liquid or solid filler involved in transporting or transporting the mold extract to enable it to perform its intended function in or to a mammal; means a veterinary acceptable substance, composition or carrier such as a stabilizer, dispersant, suspending agent, diluent, additive, thickening agent, solvent or encapsulating material. Typically, these components are carried or transported from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in terms of compatibility with other components of the formula containing the compounds useful within the invention and not causing harm to mammals. Some examples of substances that can serve as veterinary acceptable carriers include: sugars such as lactose, glucose and sucrose used in veterinary formulations; Starches such as corn starch and potato starch; Cellulose and its derivatives such as sodium carboxymethyl cellulose, ethylcellulose and cellulose acetate; tragacanth powder; malt; gelatin; talc; Additives such as cocoa butter and suppository wax; Oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; Glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; Buffering agents such as magnesium hydroxide and aluminum hydroxide; Surfactants; alginic acid; pyrogen removal water; isotonic solution; Ringer's solution; ethyl alcohol; Phosphate buffer solution; and other non-toxic combinable substances. In addition, as used in the present invention, a "veterinary acceptable carrier" is a coating agent, antiviral agent, antibacterial agent, and absorption delaying agent that is capable of combining the activity of the useful compound in the present invention and is physiologically acceptable to mammals in part or in whole. Including my back. Additionally, supplementary active compounds may be incorporated into the composition. Other additional ingredients that may be included in the veterinary compositions used in the practice of the present invention are known in the art and are described, for example, in Remington's Pharmaceutical Sciences, Genaro, Ed., Mack Publishing Co., incorporated herein by reference. , 1985, Easton, PA).
본 발명에 따른 수의학적 조성물은 수의학적 조성물의 제조에 통상적으로 사용하는 적절한 부형제 및 희석제를 더 포함할 수 있다.The veterinary composition according to the present invention may further include appropriate excipients and diluents commonly used in the preparation of veterinary compositions.
본 발명에 따른 수의학적 조성물에 포함될 수 있는 부형제 및 희석제로는, 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 세탄올, 스테아릴알콜, 유동파라핀, 솔비탄모노스테아레이트, 폴리소르베이트 60, 메칠파라벤, 프로필파라벤 및 광물유를 들 수 있다.Excipients and diluents that may be included in the veterinary composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium. Silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan mono. Examples include stearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.
본 발명에 따른 수의학적 조성물은 충진제, 항응집제, 윤활제, 습윤제, 향신료, 유화제, 방부제 등을 추가로 포함할 수 있는데, 본 발명에 의한 수의학적 조성물은 동물에 투여된 후 활성성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 사용하여 제형화될 수 있고, 제형은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 용액, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캅셀, 좌제, 멸균 주사용액, 멸균 외용제 등의 형태일 수 있다.The veterinary composition according to the present invention may further include fillers, anti-aggregants, lubricants, wetting agents, spices, emulsifiers, preservatives, etc. The veterinary composition according to the present invention provides rapid and sustained release of the active ingredients after administration to animals. or may be formulated using methods well known in the art to provide sustained release, the dosage form being powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, It may be in the form of a suppository, sterile injectable solution, or sterile topical medication.
본 발명에 따른 수의학적 조성물은 동물의 나이, 성별, 체중에 따라 달라질 수 있으나, 0.1 내지 100 mg/㎏의 양을 1일 1회 내지 수회 투여할 수 있다. 또한 형개 추출물의 투여량은 투여 경로, 질병의 정도, 성별, 체중, 나이 등에 따라서 증감될 수 있다. 따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The veterinary composition according to the present invention may vary depending on the age, sex, and weight of the animal, but may be administered in an amount of 0.1 to 100 mg/kg once or several times a day. Additionally, the dosage of Hyeonggae extract may be increased or decreased depending on the route of administration, severity of disease, gender, weight, age, etc. Accordingly, the above dosage does not limit the scope of the present invention in any way.
나아가, 본 발명의 수의학적 조성물은 고양이 전염성 복막염의 예방 및 치료 효과를 갖는 공지의 화합물과 병행하여 투여할 수 있다.Furthermore, the veterinary composition of the present invention can be administered in combination with known compounds that have preventive and therapeutic effects on feline infectious peritonitis.
본 발명은 또한 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 예방 또는 개선용 식품 조성물을 제공한다.The present invention also provides a food composition for preventing or ameliorating feline infectious peritonitis, comprising an extract of the antler as an active ingredient.
또한, 본 발명은 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 의 예방 및 개선에 유용한 동물사료 첨가제 및 이를 포함하는 사료를 제공한다.In addition, the present invention provides an animal feed additive useful for preventing and ameliorating feline infectious peritonitis, which contains the extract of the cat as an active ingredient, and a feed containing the same.
상기 동물사료 첨가제용 조성물은 20 내지 90%의 고농축액이거나 분말 또는 과립형태일 수 있다. The composition for animal feed additives may be a highly concentrated solution of 20 to 90% or may be in the form of powder or granules.
본 발명의 동물사료 첨가제는 구연산, 후말산, 아디픽산, 젖산, 사과산 등의 유기산이나 인산나트륨, 인산칼륨, 산성피로인산염, 폴리인산염(중합인산염) 등의 인산염이나 폴리페놀, 카테킨(catechin), 알파-토코페롤, 로즈메리 추출물(rosemary extract), 비타민 C, 녹차 추출물, 감초 추출물, 키토산, 탄닌산, 피틴산 등의 천연 항산화제 중 어느 하나 또는 하나 이상을 추가로 포함할 수 있다.The animal feed additive of the present invention contains organic acids such as citric acid, humalic acid, adipic acid, lactic acid, and malic acid, phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, and polyphosphate (polymerized phosphate), polyphenols, catechin, It may additionally contain any one or more of natural antioxidants such as alpha-tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, and phytic acid.
본 발명의 동물사료 첨가제 및 이를 포함하는 사료는 보조 성분으로 아미노산, 무기염류, 비타민, 항생물질, 항균물질, 항산화, 항곰팡이 효소, 살아있는 미생물 제제 등과 같은 각종 보조제가 곡물, 예를 들면 분쇄 또는 파쇄된 밀, 귀리, 보리, 옥수수 및 쌀; 식물성 단백질 사료, 예를 들면 평지, 콩 및 해바라기를 주성분으로 하는 것; 동물성 단백질 사료, 예를 들면 혈분, 육분, 골분 및 생선분; 당분 및 유제품, 예를 들면 각종 분유 및 유장 분말로 이루어지는 건조 성분, 건조 첨가제를 모두 혼합한 후, 액체 성분과 가열 후에 액체가 되는 성분, 즉, 지질, 예를 들면 가열에 의해 임의로 액화시킨 동물성 지방 및 식물성 지방 등과 같은 주성분 이외에 영양보충제, 소화 및 흡수 향상제, 성장촉진제, 질병 예방제 등과 같은 물질과 함께 사용될 수 있다.The animal feed additive of the present invention and the feed containing it contain various auxiliaries such as amino acids, inorganic salts, vitamins, antibiotics, antibacterial substances, antioxidants, anti-fungal enzymes, live microbial agents, etc. as auxiliary ingredients, such as grains, for example, crushed or crushed. wheat, oats, barley, corn and rice; Vegetable protein feeds, such as those based on rapeseed, soybean and sunflower; Animal protein feeds such as blood meal, meat meal, bone meal and fish meal; After mixing all dry ingredients and dry additives made of sugar and dairy products, such as various powdered milk and whey powder, liquid ingredients and ingredients that become liquid after heating, that is, lipids, such as animal fat optionally liquefied by heating. In addition to the main ingredients such as and vegetable fat, it can be used with substances such as nutritional supplements, digestion and absorption enhancers, growth promoters, and disease prevention agents.
상기 동물사료 첨가제는 동물에게 단독으로 혹은 식용 담체 중에서 다른 사료 첨가제와 조합되어 투여될 수 있다.The animal feed additive may be administered to animals alone or in combination with other feed additives in an edible carrier.
또한, 상기 동물사료 첨가제는 탑 드레싱으로서 또는 이들을 동물 사료에 직접 혼합하거나 또는 사료와 별도로, 별도의 경구 제형으로, 주사 또는 경피로 또는 다른 성분과 조합하여 쉽게 투여할 수 있다. 통상적으로, 당 업계에 잘 알려진 바와 같이 단독 일일 투여량 또는 분할 일일 투여량을 사용할 수 있다.In addition, the animal feed additives can be easily administered as a top dressing, by mixing them directly into animal feed, or separately from the feed, in a separate oral formulation, by injection or transderm, or in combination with other ingredients. Typically, single daily doses or divided daily doses may be used, as is well known in the art.
상기 동물사료 첨가제는 동물 사료와 별도로 투여할 경우, 당 업계에 잘 알려진 바와 같이 추출물의 투여 형태는 이들을 비-독성 제약상 허용 가능한 식용 담체와 조합하여 즉석 방출 또는 서방성 제형으로 제조할 수 있다. 이러한 식용 담체는 고체 또는 액체, 예를 들어 옥수수 전분, 락토스, 수크로스, 콩 플레이크, 땅콩유, 올리브유, 참깨유 및 프로필렌글리콜일 수 있다. 고체 담체가 사용될 경우, 추출물의 투여형은 정제, 캡슐제, 산제, 토로키제 또는 함당정제 또는 미분산성 형태의 탑 드레싱일 수 있다. 액체 담체가 사용될 경우, 연 젤라틴 캡슐제, 또는 시럽제 또는 액체 현탁액제, 에멀젼제 또는 용액제의 투여 형태일 수 있다. 또한, 투여 형태는 보조제, 예를 들어 보존제, 안정화제, 습윤제 또는 유화제, 용액 촉진제 등을 함유할 수 있다. 또한 이들은 바이러스로 인한 질환의 개선 및 예방상 유용한 다른 물질을 함유할 수 있다.When the animal feed additive is administered separately from animal feed, the dosage form of the extract can be prepared as an immediate-release or sustained-release formulation by combining them with a non-toxic pharmaceutically acceptable edible carrier, as is well known in the art. These edible carriers can be solid or liquid, such as corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol. If a solid carrier is used, the dosage form of the extract may be tablets, capsules, powders, turmeric or sugar-containing tablets or a top dressing in microdisperse form. If a liquid carrier is used, the dosage form may be a soft gelatin capsule, or a syrup or liquid suspension, emulsion or solution. Additionally, the dosage form may contain auxiliaries such as preservatives, stabilizers, wetting or emulsifying agents, solution accelerators, etc. Additionally, they may contain other substances useful for improving and preventing diseases caused by viruses.
또한, 본 발명에 따른 상기 동물사료 첨가제로 포함되는 동물사료는 동물의 식이 요구를 충족시키는데 통상적으로 사용되는 임의의 단백질-함유 유기 곡분일 수 있다. 이러한 단백질-함유 곡분은 통상적으로 옥수수, 콩 곡분 또는 옥수수/콩 곡분 믹스로 주로 구성되어 있다.Additionally, the animal feed included as the animal feed additive according to the present invention may be any protein-containing organic grain flour commonly used to meet the dietary needs of animals. These protein-containing flours typically consist primarily of corn, soybean flour, or corn/soybean flour mixes.
상기의 동물사료 첨가제는 침지, 분무 또는 혼합하여 상기 동물사료에 첨가하여 이용될 수 있다.The above animal feed additives can be used by adding them to the animal feed by dipping, spraying, or mixing.
본 발명에 따른 추출물을 포함한 동물용 사료 배합 방법은, 상기 동물사료 첨가제를 동물 사료에 건조 중량 기준으로 사료 1 ㎏당 약 1 g 내지 100 g의 양으로 혼입한다.In the method of mixing animal feed containing the extract according to the present invention, the animal feed additive is incorporated into the animal feed in an amount of about 1 g to 100 g per 1 kg of feed based on dry weight.
또한, 사료 혼합물은 완전히 혼합한 후, 성분들의 분쇄 정도에 따라 경점성의 조립 또는 과립 물질이 얻어진다. 이것을 매시로서 공급하거나, 또는 추가 가공 및 포장을 위해 원하는 분리된 형상으로 형성한다. 이 때, 저장 중에 분리되는 것을 방지하기 위해, 동물 사료에 물을 첨가하고, 이어서 통상의 펠릿화, 팽창화, 또는 압출 공정을 거치는 것이 바람직하다. 과잉의 물은 건조 제거될 수 있다.Additionally, after the feed mixture is thoroughly mixed, a lightly viscous granular or granular material is obtained depending on the degree of pulverization of the ingredients. This is supplied as a mash or formed into the desired discrete shape for further processing and packaging. At this time, in order to prevent separation during storage, it is desirable to add water to the animal feed and then subject it to conventional pelleting, expansion, or extrusion processes. Excess water can be removed by drying.
본 발명은 또한 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 예방 또는 개선용 포유동물 건강식품 조성물을 제공한다.The present invention also provides a mammalian health food composition for preventing or ameliorating feline infectious peritonitis, comprising extract of the cat as an active ingredient.
본 발명의 건강식품 조성물은 포유동물용으로서 정제, 캡슐제, 환제, 분말제 또는 액제일 수 있으며, 그 자체로 음용하거나 각종 식품이나 음료에 0.01~100 중량%의 비율로 첨가하여 사용할 수 있다. The health food composition of the present invention is for mammals and may be a tablet, capsule, pill, powder or liquid, and can be consumed on its own or added to various foods or beverages at a ratio of 0.01 to 100% by weight.
본 발명은 또한 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 바이러스에 대한 항바이러스용 조성물을 제공한다.The present invention also provides an antiviral composition against feline infectious peritonitis virus containing an extract of the cat as an active ingredient.
본 발명에 따른 상기 항바이러스용 조성물은 의약외품 조성물일 수 있다. The antiviral composition according to the present invention may be a quasi-drug composition.
본 발명의 상기 의약외품 조성물은 이에 제한되지는 않으나, 바람직하게는 소독청결제, 샤워폼, 가그린, 물티슈, 세제비누, 핸드워시, 가습기 충진제, 배변패드, 소독스프레이, 마스크, 연고제, 패치, 또는 필터 충진제일 수 있으며, 이는 고양이 전염성 복막염 바이러스를 제거하고 소독하는 용도로 활용되어, 포유동물이 고양이 전염성 복막염 바이러스에 감염되는 것을 예방할 목적, 위상생의 목적 등으로 활용이 될 수 있다. The quasi-drug composition of the present invention is not limited thereto, but is preferably used as a disinfectant cleaner, shower foam, gargle, wet tissue, detergent soap, hand wash, humidifier filler, toilet pad, disinfectant spray, mask, ointment, patch, or filter filler. It can be used for the purpose of removing and disinfecting the feline infectious peritonitis virus, preventing mammals from being infected with the feline infectious peritonitis virus, and for topological purposes.
형개 추출물을 유효성분으로 포함하는 본 발명의 조성물은 FIPV의 유래가 되는 FECV의 단백질 발현을 억제하여 FECV의 증식 및 FECV에 의한 세포 사멸 억제 능력이 우수하므로, 고양이 전염성 복막염의 예방 또는 치료제 개발에 유용하게 활용될 수 있다. The composition of the present invention, which contains the extract of the cat as an active ingredient, has an excellent ability to inhibit the proliferation of FECV and cell death caused by FECV by inhibiting the protein expression of FECV, which is derived from FIPV, and is therefore useful for the prevention or development of a treatment for feline infectious peritonitis. It can be utilized effectively.
도 1은 형개 추출물에 의해 고양이 코로나바이러스(FECV) 단백질의 발현이 억제됨을 나타낸 것이다.
도 2는 고양이 코로나바이러스(FECV)에 의한 세포 사멸이 형개 추출물에 의해 억제됨을 나타낸 것이다. Figure 1 shows that the expression of feline coronavirus (FECV) protein is suppressed by extract of Hyeonggae.
Figure 2 shows that cell death caused by feline coronavirus (FECV) is inhibited by Hyeonggae extract.
이하 본 발명을 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail. However, the following examples only illustrate the present invention, and the content of the present invention is not limited to the following examples.
실시예 1. 형개 추출물의 제조Example 1. Preparation of mold extract
형개 추출물을 제조하기 위하여, 형개 꽃이삭은 서현생약영농조합에서 구매하였다. 형개 꽃이삭을 건조시킨 후 분말로 만든 다음, 형개 분말 4g에 에탄올 40㎖을 넣고 40℃에서 3시간 동안 2회에 걸쳐 초음파 추출법을 사용하여 추출하였다. 추출된 여과액을 증발 건조하여 형개의 에탄올 추출물을 190.8mg 수득하였다.To prepare Hyeonggae extract, Hyeonggae flower spikes were purchased from Seohyeon Herbal Medicine Farming Association. After drying the flower spikes, they were made into powder, 40 ml of ethanol was added to 4 g of the flower spikes, and extracted using an ultrasonic extraction method twice for 3 hours at 40°C. The extracted filtrate was evaporated to dryness to obtain 190.8 mg of ethanol extract.
실시예 2. 형개 추출물의 코로나바이러스 증식 억제 효과 확인Example 2. Confirmation of the coronavirus proliferation inhibition effect of Hyeonggae extract
고양이 세포주인 CRFK에 코양이 코로나바이러스(FECV)를 감염시킨 후, 실시예 1에서 제조된 형개 추출물을 각각 2.5, 5, 10, 및 20 ㎍/㎖의 농도로 처리한 뒤, 72시간 후에 세포 및 세포 배양액을 수득하여 웨스턴블롯을 통해 바이러스 단백질의 발현 여부를 확인하였다. After infecting the feline cell line CRFK with feline coronavirus (FECV), the feline extract prepared in Example 1 was treated at concentrations of 2.5, 5, 10, and 20 μg/ml, respectively, and after 72 hours, the cells and Cell culture fluid was obtained and the expression of viral proteins was confirmed through Western blot.
그 결과, 도 1에서 확인할 수 있는 바와 같이, 세포에서 아무것도 처리하지 않은 대조군과 비교하여 형개 추출물를 처리하였을 때 농도 의존적으로 코로나바이러스 단백질의 발현이 현저하게 감소하였음을 확인할 수 있었다.As a result, as can be seen in Figure 1, it was confirmed that the expression of coronavirus protein was significantly reduced in a concentration-dependent manner when the cells were treated with the extract of Hyeonggae compared to the untreated control group.
실시예 3. 형개 추출물의 코로나바이러스에 의한 세포사 억제 효과 확인Example 3. Confirmation of the effect of Hyeonggae extract on inhibiting cell death caused by coronavirus
고양이 세포주인 CRFK에 코양이 코로나바이러스(FECV)를 감염시킨 후, 실시예 1에서 제조된 형개 추출물을 각각 2.5, 5, 10, 및 20 ㎍/㎖의 농도로 처리한 뒤, 72시간 후에 세포 생존율을 MTT 방법을 통하여 계산하였다.After infecting the feline cell line CRFK with feline coronavirus (FECV), the feline extract prepared in Example 1 was treated at concentrations of 2.5, 5, 10, and 20 μg/ml, respectively, and cell viability after 72 hours was calculated using the MTT method.
그 결과, 도 2에서 확인할 수 있는 바와 같이, 아무것도 처리하지 않은 경우 코로나바이러스 감염에 의해 세포 생존도가 40% 이상 감소하였으나, 형개 추출물을 처리한 군의 경우 농도 의존적으로 세포 생존도가 증가함을 확인하였다. 이로부터 형개 추출물이 코로나바이러스에 의한 세포 사멸을 억제함을 확인할 수 있었다.As a result, as can be seen in Figure 2, when nothing was treated, cell viability decreased by more than 40% due to coronavirus infection, but in the group treated with Hyeonggae extract, cell viability increased in a concentration-dependent manner. Confirmed. From this, it was confirmed that Hyeonggae extract inhibits cell death caused by coronavirus.
형개 추출물을 유효성분으로 포함하는 본 발명의 조성물은 고양이 코로나바이러스 단백질의 발현을 억제하고, 고양이 코로나바이러스에 의한 세포 사멸을 억제하는 활성이 우수하므로, 고양이 전염성 복막염의 예방 또는 치료제 개발에 유용하게 활용될 수 있어 산업상 이용가능성이 높다.The composition of the present invention containing the extract of the cat as an active ingredient has excellent activity in suppressing the expression of feline coronavirus protein and inhibiting cell death caused by feline coronavirus, so it is useful in the prevention or development of treatment for feline infectious peritonitis. It has high industrial applicability.
Claims (13)
A veterinary composition for the prevention or treatment of feline infectious peritonitis (FIP) containing ethanol extract of the dog as an active ingredient.
The veterinary composition according to claim 1, wherein the veterinary subject is a cat.
The veterinary composition of claim 1, wherein the veterinary composition is for oral, intravenous, intraperitoneal, intramuscular or subcutaneous administration.
An animal feed additive for preventing or improving feline infectious peritonitis, containing ethanol extract of the dog as an active ingredient.
Animal feed, characterized in that it contains the animal feed additive according to paragraph 4.
The food according to claim 5, wherein the food is for cats.
A mammalian health food composition for preventing or improving feline infectious peritonitis, comprising the ethanol extract of Hyeonggae as an active ingredient.
The health food composition according to claim 7, wherein the mammal is a cat.
A method of treating feline infectious peritonitis, comprising the step of administering a composition containing the ethanol extract of Hyeong-gae as an active ingredient to a mammal other than a human.
The method of claim 9, wherein the mammal is a cat.
An antiviral composition against feline coronavirus (FECV) containing the ethanol extract of the dog as an active ingredient.
The antiviral composition according to claim 11, wherein the antiviral composition is a quasi-drug composition.
The antiviral composition according to claim 12, wherein the quasi-drug is selected from the group consisting of disinfectant cleaners, shower foams, wet tissues, detergent soaps, humidifier fillers, toilet pads, and disinfectant sprays.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220131822A KR102663613B1 (en) | 2022-10-13 | Composition for preventing or treating of feline infectious peritonitis comprising Schizonepeta tenuifolia extract as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220131822A KR102663613B1 (en) | 2022-10-13 | Composition for preventing or treating of feline infectious peritonitis comprising Schizonepeta tenuifolia extract as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20240051744A KR20240051744A (en) | 2024-04-22 |
KR102663613B1 true KR102663613B1 (en) | 2024-05-16 |
Family
ID=
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3007665B2 (en) * | 1990-09-18 | 2000-02-07 | 日清製粉株式会社 | Preventive and therapeutic agent for coronavirus infection and disinfectant |
KR101651948B1 (en) * | 2015-10-06 | 2016-08-29 | 충남대학교산학협력단 | Anti-Coronavirus Composition |
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3007665B2 (en) * | 1990-09-18 | 2000-02-07 | 日清製粉株式会社 | Preventive and therapeutic agent for coronavirus infection and disinfectant |
KR101651948B1 (en) * | 2015-10-06 | 2016-08-29 | 충남대학교산학협력단 | Anti-Coronavirus Composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1965809B1 (en) | Compositions to improve gut health and animal performance comprising beta-glucans and alfa-fucans | |
US20180027843A1 (en) | Composition for drinking water agent and feed having pet urine odor removal function, comprising mixture of herbal extracts as active ingredient | |
Abd El-Hack et al. | Pharmacological, nutritional and antimicrobial uses of Moringa oleifera Lam. leaves in poultry nutrition: an updated knowledge | |
AU2017389373B2 (en) | Use of at least one glycyrrhiza plant-based preparation, an antidote made from same, and the use of said antidote | |
JPH0347132A (en) | Preventive and curing drug for protozoa disease | |
KR100887854B1 (en) | Preventives or Remedies for Arthritis | |
KR101260250B1 (en) | Anti-respiratory viral composition comprising Fritillaria thunbergii extract | |
JP6592010B2 (en) | Cancer cell growth inhibitory composition and cancer cell growth inhibitory method | |
KR20100114606A (en) | Composition for prevention or treatment of diseases caused by staphylococcus aureus | |
KR102663613B1 (en) | Composition for preventing or treating of feline infectious peritonitis comprising Schizonepeta tenuifolia extract as an active ingredient | |
KR102106477B1 (en) | Composition for preventing or treating Coccidiosis, preparation method of the same, and application of the same | |
KR20240051744A (en) | Composition for preventing or treating of feline infectious peritonitis comprising Schizonepeta tenuifolia extract as an active ingredient | |
KR102409923B1 (en) | Composition for prevention or treatment of Porcine epidemic diarrhea virus infection including a complex comprising a curcuminoid compound, and licorice extract or a fraction thereof | |
WO2021125342A1 (en) | Composition for suppressing obesity | |
KR20100021794A (en) | A veterinary composition comprising extract of rubi fructus, galla rhois, acanthopanacis cortex and paeoniae radix showing antibacterial and antiviral activity | |
KR20110122961A (en) | Composition for preventing and treating arthritis comprising hemp seed extract | |
Rahal et al. | Neem extract | |
JP2005255574A (en) | IgA-PRODUCTION-LEVELING AGENT AND STRESS DISEASE-PREVENTING AND/OR TREATING COMPOSITION CONTAINING THE SAME | |
Ibrahim et al. | Performance of Rabbits Fed Diets Containing Different Levels of Energy and Lesser Galangal(Alpinia Officinarum) | |
KR20190082581A (en) | Composition for preventing or treating infectious disease containing extract of Celastrus orbiculatus Thunb | |
JP2018168119A (en) | Cancer cell proliferation inhibitor | |
KR101637013B1 (en) | Compositions for Anti-Influenza Virus Comprising Extract of Poncirus trifoliata as Active Ingredients | |
KR101282990B1 (en) | Lipophilic fractions of green tea and green tea by product, and compound from the same with anti-influenza activity | |
JP6560471B1 (en) | Bone formation promoter and preventive and / or therapeutic agent for bone metabolic disease using the same | |
KR20230092754A (en) | Composition for treating infection of feline infectious peritonitis comprising chlortetracycline |